Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kiora Pharmaceuticals Inc (KPRX)
Price$2.55Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | $0 | $0 | $12,059 | $2.7M | $1.7M | $407,518 | $669,259 | $0 | — |
| Research & development | $10.8M | $7.8M | $4.0M | $3.4M | $5.4M | $3.6M | $5.4M | $8.1M | $10.3M | $8.4M | $2.7M | $531,116 |
| Operating expenses | $12.8M | $11.5M | $12.6M | $12.3M | $14.2M | $6.9M | $9.8M | $12.5M | $15.0M | $14.0M | $6.7M | $2.5M |
| Operating income | −$12.8M | $4.5M | −$12.6M | −$12.3M | −$14.2M | −$6.9M | — | −$10.8M | — | — | — | — |
| Operating margin | — | 28.15% | — | — | — | −56,960.51% | — | −656.25% | — | — | — | — |
| EBITDA | −$12.8M | $4.5M | −$12.5M | −$12.3M | −$14.2M | −$6.8M | — | −$10.8M | — | — | — | — |
| EBITDA margin | — | 28.27% | — | — | — | −56,683.55% | — | −653.92% | — | — | — | — |
| Net income | −$10.8M | $3.6M | −$12.5M | −$13.6M | −$13.8M | −$6.9M | −$7.1M | −$10.8M | −$13.2M | −$13.3M | −$8.4M | −$1.6M |
| Net profit margin | — | 22.44% | — | — | — | −56,901.65% | −264.21% | −654.24% | −3,243.52% | −1,993.76% | — | — |
| Basic EPSper basic share | -$2.60 | $0.93 | -$24.25 | -$1,504.06 | -$4,631.36 | -$4,832.44 | -$7,232.44 | -$14,821.64 | -$754,054.81 | -$1,224,325.55 | -$2,189,191.38 | -$7,459,466.92 |
| Diluted EPSper diluted share | -$2.64 | $0.87 | -$24.25 | -$1,504.06 | -$4,631.36 | -$4,832.44 | -$7,232.44 | -$14,821.64 | -$754,054.81 | -$1,224,325.55 | -$2,189,191.38 | -$7,459,466.92 |
Owners
Reported shareholders
9.90%of listed shares
PERCEPTIVE ADVISORS LLC438.47K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
PERCEPTIVE ADVISORS LLC | 9.90%438.47K shares |
ADAR1 Capital Management, LLC | 3.79%167.94K shares |
CITADEL ADVISORS LLC | 2.62%116.01K shares |
TWO SIGMA INVESTMENTS, LP | 2.01%88.79K shares |
MILLENNIUM MANAGEMENT LLC | 1.68%74.2K shares |
Strem Brian M. | ≈1.37%60.69K shares |
HRT FINANCIAL LP | 1.32%58.61K shares |
Daniels Eric Joseph | ≈0.72%31.74K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.67%29.82K shares |
Tosca Melissa | ≈0.61%26.98K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.60%26.72K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.45%19.86K shares |
Scientech Research LLC | 0.42%18.75K shares |
VANGUARD FIDUCIARY TRUST CO | 0.29%13.03K shares |
LPL Financial LLC | 0.28%12.5K shares |
DIMENSIONAL FUND ADVISORS LP | 0.27%12.14K shares |
NORTHERN TRUST CORP | 0.27%11.77K shares |
JANE STREET GROUP, LLC | 0.24%10.62K shares |
TYLE PRAVEEN | ≈0.11%5.01K shares |
Shapiro Aron | ≈0.07%3K shares |
Percentages use 4.43M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 11, 2024Form 4 | Stengone Carmine N.Director | BuyCommon Stock | 1.3K | $3.68 | $4.6K | 1.3K |
| Sep 10, 2024Form 4 | Shapiro AronDirector | BuyCommon Stock · indirect | 3.0K | $3.60 | $10.8K | 3.0K |
| Aug 19, 2024Form 4 | Walters-Hoffert LisaDirector | BuyCommon Stock | 1.3K | $3.86 | $4.8K | 1.3K |
| Aug 19, 2024Form 4 | TYLE PRAVEENDirector | BuyCommon Stock | 5.0K | $3.96 | $19.8K | 5.0K |
| Aug 14, 2024Form 4 | Tosca MelissaCFO | BuyCommon Stock | 2.0K | $3.21 | $6.4K | 13.6K |